Navigation Links
TVA Medical Raises $9.5 Million to Advance Minimally Invasive Therapy for End-Stage Renal Disease
Date:6/10/2013

, Managing Director at S3 Ventures.        

The surgical arterio-venous fistula (AV fistula) is the current gold-standard, but this form of access is plagued by high failure rates and frequent revisions resulting in enormous healthcare cost.  "A percutaneous AV fistula system has the potential to improve patient outcomes and drive cost out of the healthcare system," said Gerald A. Beathard, MD, PhD, pioneer of interventional nephrology from Houston, TX.

"The U.S. healthcare system spends over $47 billion annually to treat end-stage renal disease, and despite the tireless efforts of healthcare providers, only 51% of dialysis patients are still alive three years after starting therapy.  As a medical device company we believe there is an opportunity to improve outcomes for these patients while reducing healthcare costs," said Adam L. Berman, CEO of TVA Medical. The market opportunity for TVA Medical's technology exceeds $1 billion annually.

About TVA Medical
TVA Medical, Inc., headquartered in Austin, Texas, is developing minimally invasive therapies for end-stage renal disease, including a catheter-based AV fistula system.  The company was founded in 2008 by serial medical device entrepreneur and cardiovascular surgeon William (Billy) E. Cohn, MD, company CEO Adam L. Berman, and Santé Ventures.  www.TVAMedical.com

About S3 Ventures
S3 Ventures is an earlier stage venture capital firm with $170 million under management.  The firm is focused on information technology solutions that solve large business problems, and invests in medical devices that improve the human condition.  S3 primarily invests in the formative stages of a company and helps talented entrepre
'/>"/>

SOURCE TVA Medical, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Medical Specialties Distributors Acquires Medical Technology Resources
2. Vocera Chief Medical Officer Bridget Duffy Keynotes at Top Global Health Conferences
3. GRW bearing lubrication tests yield maximum wear life for medical and dental instruments
4. Study Shows Medical Devices Complicate Complex Conditions in Kids
5. ECRI Institute Launches New User Experience Network for Medical Devices
6. Blackford Capital Acquires Medical Equipment Maker Mopec, Inc.
7. Cantel Medical Reports EPS of $0.33 vs. $0.30 on 8% Sales Increase for Third Quarter Ended April 30, 2013
8. Inspiro Medical Ltd. Completes a Successful First Clinical Trial in Asthmatic Children
9. Frost & Sullivan: Standardized Regulations Crucial for Growth in Global Dimensional Metrology Market for Medical Devices
10. Chicago Crime Commission calls on Gov. Quinn to veto medical marijuana bill
11. More Than 100 Winning Medicare Bidders In Maryland Dont Have Proper Licenses To Provide Medical Equipment To Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... , Jan. 23, 2015  HyGreen, Inc., a leader ... and partnership with RCA Medical, a subsidiary of Ascendis ... . Each year, hundreds of millions of ... infections as organisms are transmitted from patient to patient ...
(Date:1/23/2015)... 2015  Lixte Biotechnology Holdings, Inc. (OTCQB: LIXT), announced that the ... Lixte,s lead compound, LB‑100, is being conducted, has been expanded ... Kovach , M.D., the founder and President of Lixte, said ... a single site. Accrual of patients, however, was slower than ...
(Date:1/23/2015)... 23, 2015  CytoSorbents Corporation (NASDAQ CM: CTSO), a ... cytokine adsorber to reduce deadly inflammation in critically-ill ... $385,642, net of transaction costs, in non-dilutive funding ... Tax Certificate Transfer Program sponsored by the New ...
Breaking Medicine Technology:HyGreen Partners with RCA Medical in Johannesburg, South Africa 2Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 2Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 3CytoSorbents Receives $385,000 in Non-Dilutive Funding from the New Jersey Technology Business Tax Certificate Transfer Program 2CytoSorbents Receives $385,000 in Non-Dilutive Funding from the New Jersey Technology Business Tax Certificate Transfer Program 3
... by end of 2007-, EDMONTON, April 16, ... it has selected PX-866 as its next ... the,phosphatidylinositol-3-kinase (PI3 kinase)/ PTEN/AKT pathway, an,important survival ... of human cancer, including glioblastoma. Preclinical data,presented ...
... - As previously announced, primary endpoint not ... treatment with ERBITUX,-, NEW YORK, April 16, ... Squibb Company today,announced detailed results from the ... III trial - comparing ERBITUX(R),(Cetuximab) plus irinotecan ...
Cached Medicine Technology:Biomira Selects PX-866 as Clinical Development Candidate and,Presents Promising Preclinical Data at AACR 2Biomira Selects PX-866 as Clinical Development Candidate and,Presents Promising Preclinical Data at AACR 3Randomized Phase III Trial Showed Erbitux Significantly Improved,Secondary Endpoints of Progression-Free Survival and Disease,Control in Metastatic Colorectal Cancer Patients 2Randomized Phase III Trial Showed Erbitux Significantly Improved,Secondary Endpoints of Progression-Free Survival and Disease,Control in Metastatic Colorectal Cancer Patients 3Randomized Phase III Trial Showed Erbitux Significantly Improved,Secondary Endpoints of Progression-Free Survival and Disease,Control in Metastatic Colorectal Cancer Patients 4Randomized Phase III Trial Showed Erbitux Significantly Improved,Secondary Endpoints of Progression-Free Survival and Disease,Control in Metastatic Colorectal Cancer Patients 5Randomized Phase III Trial Showed Erbitux Significantly Improved,Secondary Endpoints of Progression-Free Survival and Disease,Control in Metastatic Colorectal Cancer Patients 6Randomized Phase III Trial Showed Erbitux Significantly Improved,Secondary Endpoints of Progression-Free Survival and Disease,Control in Metastatic Colorectal Cancer Patients 7Randomized Phase III Trial Showed Erbitux Significantly Improved,Secondary Endpoints of Progression-Free Survival and Disease,Control in Metastatic Colorectal Cancer Patients 8Randomized Phase III Trial Showed Erbitux Significantly Improved,Secondary Endpoints of Progression-Free Survival and Disease,Control in Metastatic Colorectal Cancer Patients 9
(Date:1/22/2015)... York, New York (PRWEB) January 22, 2015 ... http://www.vaginalmeshlawsuit2015.com/ ) in the U.S. District Court, Southern District of ... C.R. Bard, Inc. in that proceeding’s first bellwether trial. In ... request for a new trial after finding that C.R. Bard ...
(Date:1/22/2015)... Autocarinsurancebest.com has released a new blog post explaining ... policy . , Auto insurance quotes help many drivers ... longer necessary to call an agent or visit an agency ... a single website: http://autocarinsurancebest.com/ . , Every business who ...
(Date:1/22/2015)... 2015 A study recently published ... journal Medicine & Science in Sports & Exercise ... help reduce gastrointestinal (GI) problems associated with physical ... in the double-blind, placebo-controlled study took 10 grams ...
(Date:1/22/2015)... Four years since the release of their debut recording Love ... of Avasa & Matthew Love – the duo are pleased to ... through White Swan Records on February 24, 2015. , THE ROAD ... available to all of us to walk out of the mire ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 JJsHouse.com is a ... dresses. Today, the business announces its latest collection of ... , “The most important issue is the wedding dress on ... thing in a woman’s life. Every bride wants to find ...
Breaking Medicine News(10 mins):Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 3Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 4Health News:Commercial Auto Insurance Provides Several Important Features! 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 3Health News:THE ROAD by Avasa & Matthew Love -- A New Album 2Health News:THE ROAD by Avasa & Matthew Love -- A New Album 3Health News:THE ROAD by Avasa & Matthew Love -- A New Album 4Health News:Find The Most Suitable Wedding Dress At JJsHouse.com 2
... was forced to take dramatic action in order to ensure that ... the local DHB began trying to get his wife's anti-nausea drug ... provided with the drug. ,Joanne Piper says that the ... Hawke's Bay hospital refused to provide enough of the drug so ...
... which manufactures contact lens solution. But recently it was found ... After this report the Food and Drug Administration ... extensive microbiological testing conducted which would take up to one ... Bausch & Lomb stopped shipping the solution, called ReNu with ...
... Gosling donated a part of his liver to a 5-year old ... //. He further stated that he had no regrets about donating ... life at risk, adding that he would do it again, if ... of his family friends is said to have been instrumental in ...
... alert has been sounded by health authorities in Tripura, ... in neighbouring Assam //. The health department of Tripura ... prevent a malaria outbreak in Tripura. ,'We ... health department. Doctors and paramedics have fanned out to ...
... is getting all the more evident after this pathbreaking ... cause obesity in children accoding to the study. // ... on this skyrocketing trend of childhood obesity, which is perhaps ... type of food advertisments targeting children. ,Nearly 5,407 students ...
... a neurodegenerative disease. According to research by physicians at ... that having close friends // and staying in contact ... damaging effects of Alzheimer's disease. The results of the ... David A. Bennett, and his colleagues is the first ...
Cached Medicine News:Health News:46-Year-Old Canada Man Donates A Part Of His Liver To A Complete Stranger 2Health News:Rush Study Shows That Interactions with Friends and Family Prevents Damaging Effects of Alzheimer's disease 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: